Pharma Focus Asia

Genevoyager Plans for the Construction of New Gene Therapy CDMO Facility in USA


Genevoyager unveils state-of-the-art gene therapy contract development and manufacturing organisation (CDMO) facility in USA.


The newly inaugurated cGMP facility boasts state-of-the-art infrastructure, featuring its proprietary One-Bac 4.0 system integrated with the Sf-RVF® cell line.

The purpose-built facility covering an 68,000 square feet is designed to streamline the process of developing, manufacturing, and scaling AAV gene therapy products. 

Its design and infrastructure are tailored specifically to support the seamless progression of these therapies from concept to market, ensuring efficient production and adherence to regulatory standards throughout every stage of the process.

With the operation of this advanced facility, comprehensive development and manufacturing services will be offered for AAV, lentivirus, oncolytic viruses, and recombinant proteins. 

This diverse range of capabilities enables the provision of tailored solutions to advance innovative biologics from conception to commercialisation, serving the needs across various therapeutic areas.


Name    Genevoyager
Type      New Construction

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference